Atlas Trials

Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer

Clinical trial NCT05908747 · COMPLETED

Trial details

NCT number
NCT05908747
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Pancreatic Cancer
Start date
2023-05-31
Primary completion
2025-05-16
Enrollment
29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.